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Despite the merits of the apparent diffusion coefficient (ADC), reporting quantitative ADC values is not a rou-
tine part of clinical practice. This is partially due to lack 
of biologic specificity (1). Recently, our group presented 
the feasibility of Vascular, Extracellular, and Restricted 
Diffusion for Cytometry in Tumors (VERDICT) MRI 
as a quantitative microstructural imaging tool for prostate 
cancer (2). VERDICT combines a diffusion-weighted 
MRI acquisition with a mathematical model and assigns 
the diffusion-weighted MRI signal to three principal com-
ponents: (a) intracellular water, (b) water in the extracellular 
extravascular space, and (c) water in the microvasculature. 
Because the fraction of each of these compartments dif-
fers between each Gleason grade (3), we hypothesized that 
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Background: Biologic specificity of diffusion MRI in relation to prostate cancer aggressiveness may improve by examining sepa-
rate components of the diffusion MRI signal. The Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors 
(VERDICT) model estimates three distinct signal components and associates them to (a) intracellular water, (b) water in the extra-
cellular extravascular space, and (c) water in the microvasculature.
Purpose: To evaluate the repeatability, image quality, and diagnostic utility of intracellular volume fraction (FIC) maps obtained 
with VERDICT prostate MRI and to compare those maps with apparent diffusion coefficient (ADC) maps for Gleason grade 
differentiation.
Materials and Methods: Seventy men (median age, 62.2 years; range, 49.5–82.0 years) suspected of having prostate cancer or under-
going active surveillance were recruited to a prospective study between April 2016 and October 2017. All men underwent multipa-
rametric prostate and VERDICT MRI. Forty-two of the 70 men (median age, 67.7 years; range, 50.0–82.0 years) underwent two 
VERDICT MRI acquisitions to assess repeatability of FIC measurements obtained with VERDICT MRI. Repeatability was mea-
sured with use of intraclass correlation coefficients (ICCs). The image quality of FIC and ADC maps was independently evaluated 
by two board-certified radiologists. Forty-two men (median age, 64.8 years; range, 49.5–79.6 years) underwent targeted biopsy, 
which enabled comparison of FIC and ADC metrics in the differentiation between Gleason grades.
Results: VERDICT MRI FIC demonstrated ICCs of 0.87–0.95. There was no significant difference between image quality of 
ADC and FIC maps (score, 3.1 vs 3.3, respectively; P = .90). FIC was higher in lesions with a Gleason grade of at least 3+4 com-
pared with benign and/or Gleason grade 3+3 lesions (mean, 0.49 6 0.17 vs 0.31 6 0.12, respectively; P = .002). The difference in 
ADC between these groups did not reach statistical significance (mean, 1.42 vs 1.16 3 1023 mm2/sec; P = .26).
Conclusion: Fractional intracellular volume demonstrates high repeatability and image quality and enables better differentiation of a 
Gleason 4 component cancer from benign and/or Gleason 3+3 histology than apparent diffusion coefficient.
Published under a CC BY 4.0 license.
Online supplemental material is available for this article.
This copy is for personal use only. To order printed copies, contact reprints@rsna.org
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VERDICT-derived metrics may provide higher biologic speci-
ficity than ADC as a marker of prostate cancer aggressiveness.
We performed this study to evaluate the repeatability, im-
age quality, and diagnostic utility of intracellular volume frac-
tion (FIC) maps obtained with VERDICT prostate MRI and 
to compare those maps with ADC maps for Gleason grade 
differentiation.
Materials and Methods
Ethical approval for the study was granted by the London– 
Surrey Borders Research Ethics Committee. The trial is reg-
istered with ClinicalTrials.gov identifier NCT02689271. Our 
institutional review board approved the study protocol, and writ-
ten informed consent was obtained from all study participants.
Our study was carried out as part of a prospective cohort 
study. The full study protocol has been published previously (4). 
Prostate Cancer UK funded the study.
Study Participants
Potentially eligible participants were identified at University 
College Hospital from a list of men scheduled to undergo 
conventional multiparametric MRI. Men meeting the eligi-
bility criteria were approached to form a consecutive series. 
Men were included if (a) there was clinical suspicion of pros-
tate cancer or (b) they were undergoing active surveillance for 
known prostate cancer. Men were excluded if (a) they had 
previously undergone treatment for prostate cancer (pros-
tatectomy, radiation therapy, brachytherapy, ablative thera-
pies), (b) they were undergoing ongoing hormonal treatment 
for prostate cancer, and (c) they had undergone biopsy within 
6 months before multiparametric MRI (4). In total, 72 men 
were recruited for VERDICT MRI between April 2016 and 
October 2017.
Two study participants were excluded due to incomplete 
VERDICT MRI data sets. Thus, imaging data from 70 par-
ticipants (median age, 62.2 years; range, 49.5–82.0 years) were 
used to form two cohorts: cohort 1, the repeatability cohort, and 
cohort 2, the biopsy cohort. A participant recruitment flow dia-
gram is presented in Figure 1.
To evaluate repeatability of VERDICT MRI metrics, a scan-
rescan repeatability study of the VERDICT MRI acquisition 
protocol was performed in 42 participants (median age, 67.7 
years; range, 50.0–82.0 years). Here, participants were imaged 
twice, with less than 5 minutes between each examination.
The biopsy study was performed to compare FIC and 
ADC metrics for the differentiation between Gleason grades. 
After clinical multiparametric MRI and VERDICT MRI, 
42 participants (median age, 64.8 years; range, 49.5–79.6 
years) underwent targeted transperineal template biopsy of 
their index lesion. Multiparametric MRI was used to guide 
cognitive targeted biopsy (performed by urologists H.U.A. 
and C.M.M., each with 7 years of targeted biopsy experi-
ence). Fourteen of the 42 patients were also included in the 
repeatability cohort. Specialist genitourinary pathologists (in-
cluding A.F. and M.R., with 13 and 15 years of prostate pa-
thology experience, respectively) evaluated histologic exami-
nations from the biopsy cores in the standard clinical fashion 
and assigned each biopsy core a Gleason grade (5). Because 
there is a clinical need to differentiate tumors with a Gleason 
4 component, we grouped results into three categories: be-
nign and/or Gleason grade 3+3 lesions, Gleason grade 3+4 
lesions, and lesions with a Gleason grade of at least 4+3.
Image Acquisition
ADC.—All participants underwent multiparametric MRI with 
a 3.0-T MRI system (Achieva; Philips, Best, the Netherlands) as 
part of their standard clinical care. A spasmolytic agent (Busco-
pan, Boehringer Ingelheim, Ingelheim am Rhein, Germany; 0.2 
mg/kg, up to 20 mg) was administered intravenously before im-
aging to reduce bowel peristalsis. Imaging parameters for the dif-
fusion-weighted echo-planar imaging sequences that generated 
the ADC map were as follows: repetition time msec/echo time 
msec, 2753/80; field of view, 220 3 220 mm; section thickness, 
5 mm; no intersection gap; acquisition matrix, 168 3 169 mm; 
b values, 0, 150, 500, and 1000 sec/mm2; and six signals ac-
quired per b value. The total imaging time for the clinical diffu-
sion-weighted sequences was 5 minutes 16 seconds. ADC maps 
were calculated by using all b values except b = 0 to reduce perfu-
sion effects (6) and were calculated with the Camino Diffusion 
MRI toolkit (7).
Full acquisition parameters for multiparametric MRI are pro-
vided in Table E1 (online).
VERDICT MRI.—VERDICT MRI was performed before dy-
namic contrast material–enhanced imaging on the same 3.0-T 
unit as the clinical multiparametric MRI acquisition. Sequences 
used an echo-planar readout, and imaging parameters were as 
Abbreviations
ADC = apparent diffusion coefficient, FIC = intracellular volume frac-
tion, ICC = intraclass correlation coefficient, PI-RADS = Prostate Imag-
ing Reporting and Data System, ROI = region of interest, VERDICT = 
Vascular, Extracellular, and Restricted Diffusion for Cytometry in 
Tumor
Summary
The intracellular volume fraction derived from Vascular, Extracellular, 
and Restricted Diffusion for Cytometry in Tumors (VERDICT) 
MRI enables better differentiation of a Gleason 4 lesion from benign 
and/or Gleason grade 3+3 lesions in prostate cancer with a high level 
of repeatability and similar image quality compared with apparent 
diffusion coefficient values.
Key Points
 n The repeatability of the Vascular, Extracellular, and Restricted 
Diffusion for Cytometry in Tumor (VERDICT) MRI model was 
high (intraclass correlation coefficient, 0.87–0.95)
 n The intracellular volume fraction in prostate lesions with a 
Gleason grade of at least 3+4 was higher than that in benign le-
sions and/or those with a Gleason grade of 3+3 (mean, 0.49 vs 
0.31, respectively; P = .002).
 n The apparent diffusion coefficients for lesions with a Gleason 
grade of at least 3+4 were not significantly different from those of 
benign lesions and/or those with a Gleason grade of 3+3 (mean, 
1.42 vs 1.16 3 1023 mm2/sec; P = .26).
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who were unaware of the study purpose, independently assessed 
anonymized randomized ADC and FIC maps (displayed in gray 
scale). Overall image quality was scored by using a subjective 
five-point ordinal scale in accordance with that reported by Hei-
jmink et al (11) and Barth et al (12). A full definition of the 
image quality scale is provided in Table E3 (online).
For the biopsy cohort, quantitative measurements of con-
trast-to-noise ratio were calculated for each index lesion accord-
ing to the study by Grussu et al (13).
Gleason Grade Differentiation with FIC and ADC
Mean quantitative ROI ADC and FIC metrics were paired 
with location-matched biopsy results as reported by the pa-
thologists. ADC and FIC values measured for each focal pros-
tate lesion were assigned to different histopathologic catego-
ries (benign, Gleason grade of 3+3, Gleason grade of 3+4, and 
Gleason grade 4+3).
Statistical Analysis
Data were analyzed with software (SPSS, version 22 [IBM, 
Armonk, NY] and GraphPad Prism 6.0e [GraphPad, La Jolla, 
Calif ]).
follows: 2482–3945/50–90; 
field of view, 220 3 220 mm; 
section thickness, 5 mm; no in-
tersection gap; acquisition ma-
trix, 176 3 176 mm; b values, 
90, 500, 1500, 2000, and 3000 
sec/mm2; and six signals ac-
quired per b value (except for b 
= 90 sec/mm2, which used four 
signals acquired). The total im-
aging time was 12 minutes 25 
seconds.
VERDICT MRI param-
eters are provided in Table E2 
(online), and further details 
regarding the biophysical basis 
and optimization of VERDICT 
have been previously described 
by Panagiotaki et al (2,8).
VERDICT MRI maps (as 
shown in Fig 2) were gener-
ated by using the accelerated 
microstructure imaging via con-
vex optimization, or AMICO, 
framework, which has previ-
ously been described by Bonet-
Carne et al (9). The methods 
used for and results of extravas-
cular extracellular volume frac-
tion and vascular volume frac-
tion analyses are presented in 
Appendix E1 (online).
Image Analysis
Multiparametric MRI lesion 
localization.—Multipara-
metric MRI studies were evaluated by a uroradiologist (S.P., 
with 10 years of prostate multiparametric MRI reporting ex-
perience) and scored by using Prostate Imaging Reporting and 
Data System (PI-RADS) version 2 (10). Where multiple le-
sions were present, the most conspicuous lesion with the high-
est PI-RADS score (3, 4, or 5) was defined as the index lesion.
Quantitative assessment of FIC and ADC.—FIC and ADC 
maps were analyzed with software (Osirix, version 8.0; Osirix, 
Pixmeo SARL, Bernex, Switzerland). A board-certified radi-
ologist (E.W.J., with 3 years of experience in multiparametric 
MRI) manually drew a region of interest (ROI) for each in-
dex lesion on each map. Where possible, additional ROIs were 
placed in PI-RADS category 1–2 lesions in the transition zone 
and peripheral zone. For evaluation of FIC repeatability, ROIs 
were copied onto maps generated from the second VERDICT 
MRI acquisition. Mean FIC and ADC values from the ROIs 
were recorded.
Assessment of FIC and ADC map image quality.—Two 
board-certified radiologists (F.G. and H.S.S., fellows in pros-
tate MRI with 5 years of experience in multiparametric MRI), 
Figure 1: Flow diagram of participant recruitment. mpMRI = multiparametric MRI, PI-RADS = Prostate 
Imaging Reporting and Data System, VERDICT = Vascular, Extracellular and Restricted Diffusion for Cy-
tometry in Tumors.
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grade 4+3 or greater. A summary of the demographic data is 
provided in Table 1.
Metric Repeatability
The ICC for FIC (first VERDICT MRI vs second VERDICT 
MRI) in PI-RADS category 1 and 2 lesions was 0.88 (95% 
confidence interval: 0.77, 0.94) in the transition zone and 0.95 
(95% confidence interval: 0.91, 0.98) in the peripheral zone. 
The ICC for FIC in PI-RADS category 3, 4, or 5 lesions was 
0.87 (95% confidence interval: 0.77, 094).
The ICCs and results of Bland-Altman analysis for other 
VERDICT-derived metrics are provided in Table E4 and Figure 
E1 (online), respectively.
Image Quality Assessment
No difference was found in overall image quality between ADC 
and FIC maps (mean score, 3.1 vs 3.3, respectively; adjusted P 
= .90). The interobserver weighted k of image quality scores was 
0.23 for FIC maps and 0.36 for ADC maps. The differences 
between mean ADC and FIC contrast-to-noise ratio were not 
statistically significant (1.84 and 1.74, respectively; P . .99).
The results of image quality assessment for other VERDICT 
metrics are provided in Table E5 and Figure E2 (online).
Gleason Grade Differentiation
The FIC and ADC values for each Gleason grade group, along 
with other VERDICT-derived parameters, are provided in 
Table E6 (online).
The distribution of ADC and FIC according to Gleason grade 
group is shown in Figure 3. The mean FIC for Gleason grade 3+4 
lesions was higher than that for benign and/or Gleason grade 
Normality was checked by using the Shapiro-Wilk test. FIC 
repeatability was assessed with intraclass correlation coefficients 
(ICCs) (1,3) and Bland-Altman analysis as recommended by 
Sullivan et al (14).
FIC and ADC map image quality scores were compared 
(together with extravascular extracellular volume fraction and 
vascular volume fraction, Appendix E1 [online]) by using the 
Friedman test with Dunn’s multiple comparison correction. The 
weighted kappa (k) was calculated to assess agreement between 
the two readers for the overall image quality review.
Analysis of variance with Bonferroni multiple comparisons 
correction was performed to determine the differences between 
three defined histopathologic categories (benign and/or Gleason 
grade of 3+3, Gleason grade of 3+4, and Gleason grade 4+3) 
for ADC and FIC. FIC and ADC receiver operating characteristic 
curves were plotted to differentiate benign and/or Gleason 3+3 
lesions from lesions with a Gleason grade of at least 3+4, and the 
area under the receiver operating characteristic curve was recorded.
Results
There were 61 index lesions in the 70 participants. Nine partic-
ipants had no focal lesion on multiparametric MRI (PI-RADS 
category 2), 28 had a PI-RADS category 3 lesion, 19 a PI-
RADS category 4 lesion, and 14 a PI-RADS category 5 lesion. 
Median prostate-specific antigen level was 7.0 ng/mL (range, 
1.0–71.0 ng/mL).
For the biopsy cohort (n = 42), the median time between 
VERDICT MRI and biopsy was 66.9 days (range, 8–167 days). 
Of the 42 biopsied index lesions, 15 were benign, five were Glea-
son grade 3+3, 11 were Gleason grade 3+4, and 11 were Gleason 
Figure 2: Images in an 82-year-old man with biopsy-proven prostate cancer arising in both the transition zone (arrows) and peripheral zone 
(arrowheads). A, Axial T2-weighted turbo spin-echo MRI shows lenticular right paramidline transition zone tumor and right peripheral zone tumor 
at 7 to 8 o’clock. Both have low signal intensity. B, Apparent diffusion coefficient (ADC) map shows that both tumors have reduced ADC. C, MRI 
obtained with b value of 2000 sec/mm2 shows tumors with high signal intensity. D, Early dynamic MRI obtained with gadolinium-based contrast 
material shows enhancement of both lesions. E, Axial Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) map of 
intracellular volume fraction shows tumors with increased intracellular volume fraction. F, VERDICT map of extracellular extravascular volume frac-
tion shows reduction in degree of extracellular extravascular space. G, VERDICT map of vascular volume fraction shows tumors with equivocal-to-
low vascular volume fraction values. Methods for determining extracellular extravascular volume fraction and vascular volume fraction, along with 
the results, are provided in Appendix E1 (online).
Johnston et al
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Summary of Demographic Data
Parameter Whole Cohort Repeatability Cohort Biopsy Cohort
No. of participants 70 42 42
Median age (y) 62 (49.5–82.0) 67.7 (50.0–82.0) 64.8 (49.5–79.6)
Median PSA level (ng/mL) 7.0 (1.0–71.0) 7.36 (3.5–30) 6.25 (1–71)
No. of focal index lesions (PI-RADS 3, 4, or 5) 61 34 42
Maximum PI-RADS score
 2 9 8 0
 3 28 16 16
 4 19 13 14
 5 14 5 12
Highest Gleason grade of biopsied index lesion
 Benign … … 15
 3+3 … … 5
 3+4 … … 11
 4+3 … … 11
Median no. of total cores … … 12 (4–27)
Median no. of sites … … 3 (1–5)
Median no. of positive cores … … 3 (0–15)
Median maximum cancer core length (mm) … … 8.5 (1–14)
Median maximum cancer core length (%) … … 77.5 (10–100)
Note.—Except where indicated, data are numbers of participants. Numbers in parentheses are ranges. PI-RADS = Prostate Imaging Report-
ing and Data System, PSA = prostate specific antigen.
Figure 3: Box-and-whisker plots show distribution of, left, apparent diffusion coefficient (ADC) (in square milli-
meters per second) and, right, Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VERDICT) 
MRI–determined intracellular volume fraction (fIC) (in fraction of signal, where 1.0 = total signal). Key differences 
in metrics between benign and/or Gleason grade 3+3 lesions and Gleason grade 3+4 lesions are shown, 
whereby P = .26 for ADC and P = .002 for intracellular volume fraction. Corrected P values for ADC after Bon-
ferroni correction were as follows: no focal lesion versus benign and/or Gleason grade 3+3 lesions, P = .011; 
no focal lesion versus Gleason grade 3+4 lesion, P  .001; no focal lesion versus lesions with Gleason grade 
4+3 or higher, P  .001; benign and/or Gleason 3+3 lesions versus focal lesions with Gleason grade 3+4,  
P = .26; benign and/or Gleason grade 3+3 lesions versus focal lesions with Gleason grade of 4+3 or higher, 
P = .047; and Gleason grade 3+4 lesions versus focal lesions with Gleason grade of 4+3 or higher, P . .99. 
Corrected P values for intracellular volume fraction after Bonferroni correction were as follows: no focal lesion 
versus benign and/or Gleason grade 3+3 lesions, P  .001; no focal lesion versus Gleason grade 3+4 lesions, 
P  .001; no focal lesion versus focal lesions with Gleason grade of 4+3 or higher, P  .001; benign and/
or Gleason grade 3+3 lesions versus focal lesions with Gleason grade 3+4, P = .002; benign and/or Gleason 
grade 3+3 lesions versus focal lesions with Gleason grade of 4+3 or higher, P = .006; and Gleason grade 3+4 
lesions versus focal lesions with Gleason grade of 4+3 or higher, P . .99.
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characteristic curve for differentiating between 
benign or Gleason grade 3+3 lesions and Gleason 
grade 3+4 or 4+3 or higher lesions were lower than 
for ADC.
Discussion
Signal on diffusion MRI is derived from contribu-
tions from intracellular water, water in the extracel-
lular extravascular space, and water in the micro-
vasculature. Because the fraction of each of these 
compartments differs between each Gleason grade 
(3), we hypothesized that Vascular, Extracellular, 
and Restricted Diffusion for Cytometry in Tumor 
(VERDICT) MRI–derived metrics may provide 
higher biologic specificity than the apparent dif-
fusion coefficient as a marker of prostate cancer 
aggressiveness. Our results showed that fractional 
intracellular volume was greater for Gleason grade 3+4 lesions 
compared with benign and/or Gleason grade 3+3 lesions (mean, 
0.49 vs 0.31, respectively; P = .002). For the same comparisons, 
the apparent diffusion coefficient showed no difference between 
groups (mean, 1.42 vs 1.16 3 1023 mm2/sec; P = .26). Further-
more, we found that the diagnostic performance of fractional in-
tracellular volume was comparable to that of the apparent diffu-
sion coefficient (area under the receiver operating characteristic 
curve, 0.93 vs 0.85, respectively) for differentiating between the 
two groups. This suggests that the fractional intracellular volume 
has an equivalent or potentially greater improved performance in 
the differentiation between disease states.
Tumors with Gleason grade 4 have distinct genomic signa-
tures (15), greater metastatic potential (16), and unfavorable 
survival outcomes (17). Metrics that can help classify cancers 
containing Gleason 4 have multiple potential clinical applica-
tions, including the noninvasive monitoring of patients with 
prostate cancer on active surveillance, more accurately avoiding 
and/or triggering biopsies, and as part of risk-stratification 
algorithms for guiding treatment decisions.
To be clinically useful, quantitative metrics must demonstrate 
good repeatability (18). FIC achieved high levels of repeatability 
(ICC  0.87) comparable to previously reported levels of ADC 
repeatability (19,20) and favorable to other diffusion models 
in prostate cancer. For example, one group (21) compared the 
repeatability of ADC with parameter estimates from stretched 
exponential, diffusion kurtosis, and biexponential models in 
the human prostate and found that although monoexponen-
tial fits and diffusion kurtosis achieved ICCs of approximately 
0.75, stretched exponential and biexponential parameters 
achieved ICCs of approximately 0.25. Another group of inves-
tigators showed that the ICCs of pseudodiffusion coefficient 
and perfusion fraction from intravoxel incoherent motion and 
a from a stretched exponential model were 0.25, 0.42, and 0.64, 
respectively, even when calculated from two sets of identical b 
values in a single acquisition (22).
Complex imaging techniques often suffer from poor image 
quality when applied more widely, yet in our cohort we found no 
significant difference in qualitative or quantitative image quality 
measures between FIC and ADC maps. This could be expected 
3+3 lesions (mean FIC, 0.49 vs 0.31, respectively; P = .002). 
The mean ADC for Gleason grade 3+4 lesions was similar to 
that for benign and/or Gleason grade 3+3 lesions (mean ADC, 
1.42 vs 1.16 3 1023 mm2/sec, respectively; P = .26). An example 
case demonstrating Gleason grade 3+4 disease on FIC and ADC 
maps is shown in Figure 4. The diagnostic performance of ADC 
and FIC for differentiating benign or Gleason grade 3+3 lesions 
from lesions with a Gleason grade of 3+4 or 4+3 or higher was 
good (area under the receiver operating characteristic curve: 0.85 
[95% confidence interval: 0.76, 0.94] and 0.93 [95% confi-
dence interval: 0.88, 0.99], respectively; P = .22) (Fig 5).
The performance of other VERDICT MRI–derived metrics 
in the differentiation of Gleason grade is provided in Figures 
E3 and E4 (online). Extravascular extracellular volume fraction 
and vascular volume fraction did not show statistically signifi-
cant differences between Gleason grade 3+3 and Gleason grade 
3+4 groups. Furthermore, the areas under the receiver operating 
Figure 4: Images in a 57-year-old man with targeted biopsy–proven Gleason 
3+4 prostate cancer. A, Apparent diffusion coefficient (ADC) map shows reduced 
ADC in left peripheral zone at 3 to 5 o’clock (arrow). B, Vascular, Extracellular, and 
Restricted Diffusion for Cytometry in Tumors (VERDICT) intracellular volume fraction 
map. Tumor (arrow) is very conspicuous.
Figure 5: Receiver operating characteristic curves and correspond-
ing area under the curve values for apparent diffusion coefficient 
(ADC) and intracellular volume fraction measurement (fIC) obtained 
with Vascular, Extracellular, and Restricted Diffusion for Cytometry in 
Tumors MRI to differentiate benign and/or Gleason grade 3+3 pros-
tate lesions from lesions with Gleason grade of 3+4 or 4+3 or higher.
Johnston et al
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as both techniques use the same echo-planar imaging readout 
to generate images. To our knowledge, two studies have evalu-
ated image quality in prostate multiparametric MRI and used 
a similar five-point scale to assess the overall image quality of 
ADC images (11,12). These studies showed a mean image qual-
ity score of 3.18 and 3.03, respectively; thus, the quality of our 
ADC and FIC images (mean image quality score, 3.06 and 3.30, 
respectively) was comparable to those found in the literature.
The main limitation of our study is the number of participants 
and time constraints which precluded performing ADC repeat-
ability as a comparator. However, similar studies have had eight 
or fewer study participants (23), which emphasizes that interval 
repeatability examinations are difficult to perform given partici-
pant tolerance issues and time limitations of clinical workflows 
(where we were allocated a 1-hour imaging slot). Small sample 
size likely limited our ability to examine differences in diagnostic 
performance (assessed with comparison of areas under the receiver 
operating characteristic curve) for FIC and ADC values.
In summary, intracellular volume fraction determined with 
Vascular, Extracellular, and Restricted Diffusion for Cytometry in 
Tumor (VERDICT) MRI enables better differentiation of Glea-
son 4 lesions from benign and/or Gleason 3+3 lesions in prostate 
cancer with a high level of repeatability and an image quality sim-
ilar to that of apparent diffusion coefficient values. Reproducibil-
ity and multicenter clinical evaluation remain the next steps in 
VERDICT development (18).
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